Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population-based incidence of childhood leukaemias and lymphomas in Spain (1993-2002).
Marcos-Gragera R, Cervantes-Amat M, Vicente ML, de Sanjosé S, Guallar E, Godoy C, Calvo C, Giraldo P, Sant M, Peris-Bonet R, Carmen Martos M. Marcos-Gragera R, et al. Among authors: giraldo p. Eur J Cancer Prev. 2010 Jul;19(4):247-55. doi: 10.1097/CEJ.0b013e328339e2f3. Eur J Cancer Prev. 2010. PMID: 20395866
Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States.
Sant M, Allemani C, De Angelis R, Carbone A, de Sanjosè S, Gianni AM, Giraldo P, Marchesi F, Marcos-Gragera R, Martos-Jiménez C, Maynadié M, Raphael M, Berrino F; EUROCARE-3 Working Group. Sant M, et al. Among authors: giraldo p. Eur J Cancer. 2008 Mar;44(4):579-87. doi: 10.1016/j.ejca.2007.12.016. Epub 2008 Jan 31. Eur J Cancer. 2008. PMID: 18242077
Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project.
Marcos-Gragera R, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Maynadie M, Luminari S, Ferretti S, Johannesen TB, Sankila R, Karjalainen-Lindsberg ML, Simonetti A, Martos MC, Raphaël M, Giraldo P, Sant M; HAEMACARE Working Group. Marcos-Gragera R, et al. Among authors: giraldo p. Haematologica. 2011 May;96(5):720-8. doi: 10.3324/haematol.2010.034264. Epub 2011 Feb 17. Haematologica. 2011. PMID: 21330324 Free PMC article.
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Santamaría C, Chillón MC, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizán JA, Peñarrubia MJ, Giraldo P, San Miguel JF, Gonzalez M. Santamaría C, et al. Among authors: giraldo p. Haematologica. 2008 Dec;93(12):1797-805. doi: 10.3324/haematol.13214. Epub 2008 Sep 24. Haematologica. 2008. PMID: 18815192 Free article.
Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
Steegmann JL, Odriozola J, Rodriguez-Salvanés F, Giraldo P, García-Laraña J, Ferro MT, Benítez E, Pérez-Pons C, Giralt M, Escribano L, Lavilla E, Miguel A, Areal C, Pérez-Encinas M, Abad A, Maldonado J, Massagué I, Fernández-Rañada JM. Steegmann JL, et al. Among authors: giraldo p. Haematologica. 1999 Nov;84(11):978-87. Haematologica. 1999. PMID: 10553157 Clinical Trial.
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
Chillón MC, Santamaría C, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Marín L, Caballero MD, Vidriales MB, Ramos F, Bernal T, Díaz-Mediavilla J, García de Coca A, Peñarrubia MJ, Queizán JA, Giraldo P, San Miguel JF, González M. Chillón MC, et al. Among authors: giraldo p. Haematologica. 2010 May;95(5):745-51. doi: 10.3324/haematol.2009.015073. Epub 2010 Feb 4. Haematologica. 2010. PMID: 20133893 Free PMC article.
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF, García-Gutiérrez JV, Massagué I, Giraldo P, Pérez-Encinas M, de Paz R, Martínez-López J, Bautista G, Osorio S, Requena MJ, Palomera L, Peñarrubia MJ, Calle C, Hernández-Rivas JÁ, Burgaleta C, Maestro B, García-Ormeña N, Steegmann JL. Casado LF, et al. Among authors: giraldo p. Cancer Med. 2015 Jul;4(7):995-1002. doi: 10.1002/cam4.440. Epub 2015 Mar 10. Cancer Med. 2015. PMID: 25756742 Free PMC article.
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
Garcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B, Giraldo P, Angona A, Alvarez-Larrán A, Sanchez-Guijo F, Ramírez MJ, Mora E, Vélez P, Rosell A, Colorado Araujo M, Cuevas B, Sagüés M, Cortes M, Encinas MP, Casado Montero LF, Moreno Vega M, Serrano L, Gomez V, Garcia-Hernandez C, Lakhwani S, Paz Coll A, de Paz R, Suarez-Varela S, Fernandez-Ruiz A, Perez Lopez R, Ortiz-Fernández A, Jiménez-Velasco A, Steegmann-Olmedillas JL, Hernández-Boluda JC. Garcia-Gutiérrez V, et al. Among authors: giraldo p. Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8. Blood Cancer J. 2021. PMID: 33563899 Free PMC article. No abstract available.
395 results